The study, published in JAMA Network Open on Jan. 5, looked at COVID-19 and MIS-C hospitalizations in 31 states between February and October 2021 for individuals younger than 21. There were 4,107 individuals with MIS-C and 23,686 individuals with COVID-19 without MIS-C.
The study compared reported numbers in their analysis. They found the following as the number of organ systems affected increased from two to six or more:
- Mortality from MIS-C increased from 1 percent to 6 percent.
- Adverse medication events due to MIS-C increased from 5 percent to 18 percent.
- The length of stay doubled from four to eight days for MIS-C patients.
- Median costs for MIS-C increased from $16,225 to $53,359.
- The percentage of patients with MIS-C who were Black doubled from 16 percent to 32 percent.
- Hospital stays for MIS-C increased by one day for Black patients compared with White patients, with Black patients moving from the bottom to top quartile of socioeconomic vulnerability, with no disparity with COVID-19.
- Researchers concluded that relying on mean outcomes for MIS-C from past studies can be misleading, because outcomes and disparities varied widely with the number of multiorgan dysfunctions, according to the report.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
